Biolase Revenue 2010-2024 | BIOL

Biolase revenue from 2010 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Biolase Annual Revenue
(Millions of US $)
2023 $49
2022 $48
2021 $39
2020 $23
2019 $38
2018 $46
2017 $47
2016 $52
2015 $48
2014 $48
2013 $56
2012 $57
2011 $49
2010 $26
2009 $43
Biolase Quarterly Revenue
(Millions of US $)
2024-03-31 $10
2023-12-31 $13
2023-09-30 $11
2023-06-30 $14
2023-03-31 $10
2022-12-31 $14
2022-09-30 $12
2022-06-30 $12
2022-03-31 $10
2021-12-31 $12
2021-09-30 $10
2021-06-30 $9
2021-03-31 $8
2020-12-31 $9
2020-09-30 $7
2020-06-30 $3
2020-03-31 $5
2019-12-31 $10
2019-09-30 $9
2019-06-30 $9
2019-03-31 $10
2018-12-31 $13
2018-09-30 $11
2018-06-30 $12
2018-03-31 $10
2017-12-31 $13
2017-09-30 $11
2017-06-30 $13
2017-03-31 $11
2016-12-31 $14
2016-09-30 $13
2016-06-30 $14
2016-03-31 $11
2015-12-31 $15
2015-09-30 $11
2015-06-30 $12
2015-03-31 $11
2014-12-31 $13
2014-09-30 $13
2014-06-30 $10
2014-03-31 $12
2013-12-31 $15
2013-09-30 $12
2013-06-30 $14
2013-03-31 $15
2012-12-31 $19
2012-09-30 $14
2012-06-30 $12
2012-03-31 $12
2011-12-31 $13
2011-09-30 $13
2011-06-30 $12
2011-03-31 $11
2010-12-31 $10
2010-09-30 $6
2010-06-30 $6
2010-03-31 $4
2009-12-31 $10
2009-09-30 $12
2009-06-30 $14
2009-03-31 $7
Sector Industry Market Cap Revenue
Medical Medical & Dental Supplies $0.006B $0.049B
Biolaw Technology, Inc. is the world's leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies that advance the practice of dentistry and medicine. The Company's products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets.
Stock Name Country Market Cap PE Ratio
McKesson (MCK) United States $72.451B 20.33
Becton Dickinson (BDX) United States $67.758B 19.17
West Pharmaceutical Services (WST) United States $24.351B 43.64
Cardinal Health (CAH) United States $23.460B 13.41
Align Technology (ALGN) United States $19.658B 37.95
Cooper (COO) United States $19.200B 29.05
Labcorp (LH) United States $16.960B 14.60
Henry Schein (HSIC) United States $9.268B 16.49
DENTSPLY SIRONA (XRAY) United States $5.824B 15.08
Merit Medical Systems (MMSI) United States $4.773B 26.16
CONMED (CNMD) United States $2.309B 20.94
Patterson (PDCO) United States $2.193B 10.51
STAAR Surgical (STAA) United States $2.091B 80.28
Atrion (ATRI) United States $0.831B 44.36
Lifevantage (LFVN) United States $0.095B 12.25
Pro-Dex (PDEX) United States $0.067B 33.88